NEW YORK, June 27, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Ohr Pharmaceutical, Inc. (NASDAQ: OHRP), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Arrowhead Research Corp. (NASDAQ: ARWR), CytRx Corporation (NASDAQ: CYTR) and Karyopharm Therapeutics, Inc. (NASDAQ: KPTI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4203-100free.
--
Ohr Pharmaceutical, Inc. Analyst Notes
On June 24, 2014, Ohr Pharmaceutical, Inc. (Ohr) announced positive top-line interim results for its double-masked, placebo-controlled Phase II clinical trial of Squalamine eye drops in patients with wet age-related macular degeneration (wet AMD). According to the Company, patients that were treated with Squalamine eye drops plus Lucentis® PRN demonstrated a 65% additional relative benefit in visual acuity versus placebo eye drops plus Lucentis PRN. Ohr President and CEO, Dr. Irach B. Taraporewala, said, "The data further validate not only the clinical utility of non-invasive topical eye drop therapies for macular and retinal disorders, but also the soundness of our company's drug development science, and our proprietary formulation technologies that enable topical dosing to achieve positive therapeutic effects in back-of-the-eye disorders." The Company stated that it plans to present the full data from this interim analysis in H2 2014, and final clinical trial data is expected in Q1 2015. The full analyst notes on Ohr are available to download free of charge at:
http://www.analystsreview.com/Jun-27-2014/OHRP/report.pdf
--
Ariad Pharmaceuticals Inc. Analyst Notes
On June 23, 2014, Ariad Pharmaceuticals Inc. (Ariad) announced that the Company has appointed Timothy Maines as Vice President, Quality; Yan Moore, M.D. as Vice President, Medical Affairs; and Piet A.M Vervaet, M.D. as Vice President, Drug Safety and Pharmacovigilance. Commenting on the appointments, Ariad Chairman and CEO, Harvey J. Berger, M.D., stated, "As we continue to strengthen our oncology business in the United States and Europe, the recruitment of these three executives to our management team demonstrates our commitment to building a highly successful commercial oncology business. They exemplify our core values and bring many years of highly relevant experience to ARIAD in areas of fundamental importance to the Company. I am pleased to welcome Tim, Yan and Piet to ARIAD and look forward to their important contributions to our business." The full analyst notes on Ariad are available to download free of charge at:
http://www.analystsreview.com/Jun-27-2014/ARIA/report.pdf
--
Arrowhead Research Corp. Analyst Notes
On June 24, 2014, Arrowhead Research Corp.'s (Arrowhead) stock went down by 5.71%, ending the day at $14.19. However, for the past five-day trading period, Company's stock increased by 1.50% compared to the Nasdaq Composite which went up by 0.30% during the same trading session. The full analyst notes on Arrowhead are available to download free of charge at:
http://www.analystsreview.com/Jun-27-2014/ARWR/report.pdf
--
CytRx Corporation Analyst Notes
On June 24, 2014, CytRx Corporation's (CytRx) stock lost 6.88%, closing at $4.33. Over the previous three-day trading session, CytRx's stock dipped by 12.70% compared to the Nasdaq Composite which decreased by 0.21% during the same trading period. The full analyst notes on CytRx are available to download free of charge at:
http://www.analystsreview.com/Jun-27-2014/CYTR/report.pdf
--
Karyopharm Therapeutics, Inc. Analyst Notes
On June 24, 2014, Karyopharm Therapeutics, Inc. (Karyopharm Therapeutics) announced that it has initiated its Phase 2 study of Selinexor (KPT-330) in patients 60 years of age or older with relapsed or refractory acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy and/or transplantation. According to the Company, in the Selinexor in Older Patients with Relapsed/Refractory AML (SOPRA) study, 150 patients with AML which has relapsed after, or was refractory to, first line therapy will be randomized 2:1 to Selinexor provided orally twice a week with a dosage of 55mg/m2 versus one of four physician choices. The Company informed that overall survival is the primary endpoint. Founder, President and CSO of the Company, Dr. Sharon Shacham, said, "The initiation of this first registration-directed study of Selinexor represents a major milestone for Karyopharm." The full analyst notes on Karyopharm Therapeutics are available to download free of charge at:
http://www.analystsreview.com/Jun-27-2014/KPTI/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
